NexGel reports flat Q3 revenue of $2.9 million; narrows adjusted EBITDA loss to $354,000 while forecasting strong Q4 growth driven by new product launches.

OPERATOR - (00:00:00)

We apologize for the hold to all locations. We do appreciate your patience and please continue to stand by.

Bo - Conference Operator - (00:01:51)

Please stand by. We're about to begin. Good afternoon everyone. My name is Bo and I will be your conference operator. Today. At this time I would like to welcome everyone to NexGel's third quarter 2025 financial results conference call. At this time I'll turn things over to Mr. Valter Pinto, Managing Director of KCSA Strategic Communications. Please go ahead, sir.

Valter Pinto - Managing Director - (00:02:15)

Thank you, operator. Good afternoon and welcome everyone to NexGel's third quarter 2025 financial results conference call. I'm joined today by Adam Levy, Chief Executive officer and Joe McGuire, Chief Financial Officer. Before we begin, I'd like to remind everyone that statements made during today's conference call may be deemed forward looking statements within the meaning of the safe harbor of the Private Securities Litigation Reform act of 1995, and actual results may differ materially due to a variety of risks, uncertainties and other factors. For a detailed discussion of some of the ongoing risks and uncertainties in the Company's business, I refer you to the press release issued this evening and filed with the SEC on Form 8K, as well as the Company's reports filed periodically with the SEC. The Company disclaims any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by law. Also, during the course of today's call, we will refer to certain non GAAP financial measures. Reconciliation of the non GAAP to GAAP financial measures and certain additional information are also included in today's press release. With that, it's my pleasure to turn the call over to Mr. Adam Levy. Adam, please go ahead.

Adam Levy - Chief Executive Officer - (00:03:25)

Thank you, Valter. And thank you everyone for joining us today to discuss our third quarter 2025. Financial and operating results. For the third quarter of 2025, we reported revenue of 2.9 million flat year over year and slightly higher sequentially. While our revenue remained steady during both periods, gross profit margins improved year over year, coming in again in the low 40s for the third quarter. And our adjusted EBITDA loss trend continued to narrow sequentially from a loss of 500,000 in Q1 to 419,000 in Q2 and now in Q3 to 354,000. Consistent performance in contract manufacturing and consumer branded products while maintaining discipline and consistently improving our operational efficiencies were key factors in these results. I'll now provide an update on both our contract manufacturing and consumer branded product businesses. Starting with contract manufacturing, this segment of business has played a pivotal role in our growth, led by increased demand from existing customers as well as the successful onboarding of several new global corporations. For the third quarter, contract manufacturing revenue totaled 907,000, a slight increase year over year and sequentially. Our performance in contract manufacturing is led by our ongoing relationship with Cintas, which remains strong and our Silver Seal product continuing to be included in their wound care kits and cabinets for businesses throughout the country. We began shipping initial orders to Cintas in Q4 of last year and reorders for deliveries have continued each subsequent quarter and remain strong and steady. This partnership reflects the consistent value our advanced hydrogel technology brings to Cintas customers and underscores our commitment to long term recurring commercial relationships. The Institutional review Board study, conducted under FDA guidelines and funded by our partner Innovative Optics, is complete and we are waiting on final data to be published. This 30 patient clinical trial evaluated the use of our hydrogels when applied prior to laser hair removal treatments. The primary goal of the study was to assess its efficacy in reducing the release of carcinogenic plume during these procedures. We have been in contact with the Journal and do expect publication before year end. As many of you know, in May we signed an agreement with iRhythm, a publicly listed company on the Nasdaq and a leading digital healthcare company that creates trusted solutions that detect, predict and prevent disease to supply our hydrogels as part of their XYO ECG Heart monitoring system. XYO is a single use ECG heart monitor that provides a continuous single channel recording for up to 14 days. The monitor is worn on the patient's upper left chest and it features NexGel's advanced hydrogel. After the conclusion of the 14 day monitoring period, the patient simply removes the device and mails it back to iRhythm for analysis. We anticipate iRhythm's first direct orders from us this quarter. The integration of our hydrogels into Irhythm XYO Heart Monitor showcases another impactful application for our skin friendly, dermatologically safe technology. We look forward into growing this relationship as iRhythm scales their product. There are many other opportunities we are actively pursuing. Our new customer pipeline remains robust with several of them now approaching launch. We expect contract manufacturing and white label to continue being a major driver of. Our expansion and success moving forward. Turning our attention to our consumer products segment. Revenue remains stable year over year and sequentially during the quarter. There were some unforeseen logistical delays that affected the movement of inventory which delayed some of our product launches until late September. These have all been resolved and we anticipate a very strong fourth quarter including these new products in late Q2. Heading into Q3, we began to see strong performance from the first of Silly George's new product launches we previewed earlier this year. In addition to the continued growth of our core Lash offerings, we introduced an expanded beauty line of five new shades of lip gloss. While we only launched our new lip gloss in very late September, the launch has gone well so far and we are looking forward to seeing how this product does as we head into the holiday season along with our other new product offerings. Similarly, KenkoDerm will double the size of its product portfolio with the launch of new products expanding into solutions for eczema, tapping into an even larger market opportunity for the brand that is leveraging its strong reputation as a leader in sensitive skin care. We expect these new products to hit the market in the next few months. MediGel has expanded its product line with the launch of several new offerings, including the Silver Seal Wound and Burn Kit and the Moist Burn Pads. These products are doing extremely well on Amazon and we look forward to their continued growth. We have also just received approval from Health Canada to sell Silverseal in that territory. Lastly, we could not be more excited about our expanding partnership with STADA, a European leader in consumer health. Building on the strong performance of histasolve, we recently amended our agreement to broaden the collaboration considerably. Together with STADA, we are planning to soft launch one new product in December, with several more slated for early 2026. Gluticin, a digestive enzyme for gluten sensitivity, will be the product soft launched in December with a full marketing and promotional plan for January. This next phase of the partnership includes the planned launches of additional digestive enzymes, formulas and and skin care solutions targeting scars and stretch marks, products we're now positioned to bring to the North American market. As you all know, STADA provided 1 million in non dilutive financing that is. Now on our balance sheet to support the upcoming product launches and marketing initiatives. A show of confidence in our partnership Before I turn the call over to. Joe for a review of our financial. Results for the third quarter, I would like to discuss our outlook for the fourth quarter and full year. For the fourth quarter we do expect revenues to increase sequentially and Q4 will be a record quarter for the company. However, conservatively as we sit today, I expect full year 2025 revenues of between 12 and 12.5 million with the higher end of the range taking into account. A strong consumer branded products holiday season. As I have said many times, for me, even more important than top line growth is a path to profitability. In the third quarter we narrowed our adjusted EBITDA loss to 354,000 and with the sequential growth that I expect in Q4, I see that narrowing even further to very close to adjusted EBITDA. Breakeven thank you to our shareholders for your ongoing confidence in our team and mission. Your support remains essential as we continue to execute our growth strategy and build long term value together. I would now like to turn the call over to Joe McGuire, our chief financial Officer.

Joe McGuire - Chief Financial Officer - (00:10:40)

Thank you Adam. Today I'll review our key financial Results for the third quarter of 2025 for the third quarter of 2025, revenue totaled 2.9 million flat as compared to 2.9 million for the third quarter of 2024. Contract manufacturing and branded product revenue remained stable year over year. Cost of revenues totaled 1.7 million for the third quarter of 2025 as compared to 1.8 million for the third quarter of 2024, a decrease of 5.2%. The decrease in cost of revenues is primarily due to a decrease in materials and finished products and a decrease in amortization and depreciation offset by an increase in commission and contract fees and an increase in equipment production and other expenses. Gross profit totaled 1.24 million for the third quarter of 2025, slightly higher than gross profit of 1.16 million for the third quarter of 2024. Gross profit margin for the third quarter of 2025 was 42.4%, an increase as compared to 39.3% for the third quarter of 2024. Selling general and administrative expenses towed 1.96 million for the third quarter of 2025 as compared to 1.94 million for the third quarter of 2024. The slight increase year over year is primarily attributable to increased compensation and benefits, fair based compensation and professional and consulting fees offset by a decrease in advertising, marketing and Amazon fees. EBITDA loss, a non GAAP financial measure, totaled negative 550,000 compared to negative 533,000 for the second quarter of 2025 and negative 577,000 for the first quarter 2025. Adjusted EBITDA loss, a non GAAP financial measure, totaled negative 354,000 compared to negative 419,000 for the second quarter 2025 and negative 500,000 for the first quarter of 2025. Net loss attributable to NexGel stockholders for the third quarter of 2025 was 653,000 as compared to a net loss of 693,000 for the third quarter of 2024. As of September 30, 2025, the Company held a cash balance of approximately 938,000 and a restricted cash balance of 920,000 related to receiving 1,000,000 in non dilutive capital from STADA to support upcoming product launches and marketing efforts. As of November 10, 2025, NexGel had 8,143,133 shares of common stock outstanding. I would now like to open the call for questions. Operator.

OPERATOR - (00:14:00)

Thank you very much, Mr. McGuire. Ladies and gentlemen, at this time, if you do have any questions, please press Star one at this time. And if you find your question has been addressed, you can always remove yourself from the queue by pressing Star two. Once again, Star one for questions. We'll go first this afternoon to Naz Rahman with the Maxim Group.

Naz Rahman - Equity Analyst - (00:14:18)

Hi everyone. Thanks for taking my questions. I just have a few. First, I just want to start on the logistical delays you mentioned. Could you elaborate a little bit more on that? Like how many days worth of sales did it impact and I guess how much could those sales have been worth? I guess I'm trying to get a sense of what the underlying demand could have been or the impact.

Adam Levy - Chief Executive Officer - (00:14:41)

So. Hi, it's good to hear from you again. So the total delay was it varied on different products. A lot of it had to do. With stuff getting stuck in customs and. Trying to create, you know, new ways of getting the product into the country because everything was sort of held up with the new regulations and changing it probably impacted the existing products not too severely. But where it really mattered was we were hoping for a late August early release on the lip gloss. As a result, it was only released on September 27, right at the very. End of the quarter. And that happened with a couple of products. So, you know, you're probably talking about 100 to $200,000 maybe depending on, you know, what, what it would have done during that period of time. So, you know, not devastating, but it was frustrating at the time.

Naz Rahman - Equity Analyst - (00:15:33)

Got it, thanks. And just kind of going off that. So I think on the call you said you expect you Revised, got into 12 to 12 and a half for the full year. Obviously the last couple quarters have been flat. I guess what kind of gives you confidence in, in that number now, especially like the top end of that number. Are you seeing any tailwinds or any data points I would suggest you could get there? Or is it more just the seasonality you expect.

Adam Levy - Chief Executive Officer - (00:15:59)

No, actually and this is a great point which is we appear to be and we are flat from third quarter last year to third quarter this year. But understand in third quarter last year. And fourth quarter last year we launched. With two new customers on the contract. Manufacturing side that were quite large. So Q3 of last year was a record for us because Owens and Miner was onboarded. And for example, and I'll use this just as an example with round numbers in Q4 we had very, very large sales, call it $400,000 from the initial orders of Cintas. Well, this year the initial orders of Owens, the initial order of Cintas are replaced by repeat orders at about 50% of the size and volume. The reason we're flat is because the rest of the business is still growing, the rest of the customers are still growing. So without onboarding anybody in Q3 we maintained where we are well in Q4, yes, we're going to have that drop but we still have the growth offsetting it of the rest of the products and we'll be shipping some new customers like iRhythm. So we already kind of know that the fourth quarter will be a very large contract manufacturing quarter and will be up. What we're not as sure about is how big are the new products and. The existing products going to do during the holiday season. That's always the wild card with the economy and everything else. So that's really, you know, we know it's going to be fourth quarter is always the strongest. We know sales will also increase there. Just how much is difficult to tell. Does that answer the question?

Naz Rahman - Equity Analyst - (00:17:31)

Got it. That was helpful. And one last question if I may. I know previously you were talked, you talked about AbbVie and the Resonate device. I know Abby took a large impairment charging as a Resonate device recently. Do you know if they're still planning on launching a product and just what's kind of going on with that?

Adam Levy - Chief Executive Officer - (00:17:49)

So it's really puzzling and very frustrating. On October 24th I received a email. From AbbVie saying that they put in the Request for Quotation (RFQ) and that we'd be receiving our first Purchase Order (PO) shortly which I was hoping to announce on this call and then I've heard from others that they've actually taken that charge. So I'm not sure where ABBVIE stands. It might be the worst case of one hand not knowing what the other hand is doing that I've ever seen. But it is a frustrating situation trying to get to the bottom of it. But I'm very concerned about it and honestly, I really don't know.

Naz Rahman - Equity Analyst - (00:18:24)

Okay, understood. Thanks for taking my questions.

Adam Levy - Chief Executive Officer - (00:18:26)

Sure.

OPERATOR - (00:18:29)

Thank you. And just a quick reminder, everyone, Star one for questions today. We'll go next now to Kurt and Patel, private investor.

Kurt Patel - Private Investor - (00:18:41)

Yes, I have a question. So what is the current order book like from the contract manufacturing side?

Adam Levy - Chief Executive Officer - (00:18:54)

So it's strong. I don't want to get into too much details as to what it is, but all of the existing customers continue to order. We're seeing growth, you know, along the cagrs of their growth of their medical devices across the entire segment. We've got a pretty robust and full pipeline of potential new customers, some of whom will be onboarding this quarter, next quarter. So we're very bullish on how our contract manufacturing is going to grow over the next two or three quarters. At least we have visibility that far out.

Kurt Patel - Private Investor - (00:19:23)

Got it. And do you have, you still have a strong cash position to be able to fulfill that orders?

Adam Levy - Chief Executive Officer - (00:19:32)

Yes. Yeah. And contract manufacturing orders are something that we do very well. We built our inventory dramatically on both the consumer product side and on the raw material side for the contract manufacturing in Q3. So now Q4 is where we start to recoup some of that money, reduce those receivables somewhat, reduce that inventory somewhat by shipping the products and then collect the receivables. So Q4 has generally been a very strong cash sort of position for us because you do get all of those direct to consumer sales that you get paid very, very quickly. And we have built inventory for what we think will be a very strong quarter. So as we move through that inventory, that will help our cash position even further.

Kurt Patel - Private Investor - (00:20:12)

Got it. And from your last quarter, are you still expecting to achieve a positive EBITDA during the by end of the year or has that changed?

Adam Levy - Chief Executive Officer - (00:20:22)

Yeah, we think so. If not, it's going to be super close, but we think it's really going to depend on the consumer products. We think that, you know, we were. Hoping to chop more off, I'll be honest with you, I was hoping to chop more off in Q3 than we did. But with the, with the, what we. See coming is a very strong fourth quarter in contract as well as if we can get a very good quarter in terms of consumer products in Q4. I think we have a chance to get there. We'll see.

Kurt Patel - Private Investor - (00:20:50)

Got it. Thank you. And that's about it. Thank you so much.

Adam Levy - Chief Executive Officer - (00:20:54)

Sure. Thank you.

OPERATOR - (00:20:58)

Thank you. And just a final reminder, ladies and gentlemen, any further questions this afternoon, please press Star one and we'll pause for just one moment. And, gentlemen, it appears we have no further questions this afternoon. So that will bring us to the conclusion of today's next JEL third quarter, 2025 financial results call. We'd like to thank everyone for joining us this afternoon and wish you all a great remainder of your day. Goodbye.